Justin Taylor
Overview
Explore the profile of Justin Taylor including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
113
Citations
2478
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Kahn S, Huff M, Taylor J, ONeill K, Hink A, Mittal R, et al.
J Am Coll Surg
. 2025 Feb;
PMID: 39902941
Background: Fresh frozen plasma (FFP) as an adjunct in burn resuscitation to decrease endothelial cell permeability by restoring the glycocalyx is not yet standard of care, despite increasing evidence showing...
2.
3.
Stanchina M, Montoya S, Danilov A, Castillo J, Alencar A, Chavez J, et al.
Nat Rev Clin Oncol
. 2024 Nov;
21(12):867-887.
PMID: 39487228
The B cell receptor (BCR) signalling pathway has an integral role in the pathogenesis of many B cell malignancies, including chronic lymphocytic leukaemia, mantle cell lymphoma, diffuse large B cell...
4.
Allowitz K, Taylor J, Harames K, Yoo J, Baloch O, Ramana K
Curr Neuropharmacol
. 2024 Oct;
PMID: 39440770
Neurodegenerative diseases such as Alzheimer's, Parkinson's, and amyotrophic lateral sclerosis cause damage and gradual loss of neurons affecting the central nervous system. Neurodegenerative diseases are most commonly seen in the...
5.
Komrokji R, Lanino L, Ball S, Bewersdorf J, Marchetti M, Maggioni G, et al.
Lancet Haematol
. 2024 Oct;
11(11):e862-e872.
PMID: 39393368
The WHO and International Consensus Classification 2022 classifications of myelodysplastic syndromes enhance diagnostic precision and refine decision-making processes in these diseases. However, some discrepancies still exist and potentially cause inconsistency...
6.
Aakash F, Gisriel S, Zeidan A, Bennett J, Bejar R, Bewersdorf J, et al.
Mod Pathol
. 2024 Sep;
37(12):100615.
PMID: 39322118
Myelodysplastic neoplasms/syndromes (MDS) are a heterogeneous group of biologically distinct entities characterized by variable degrees of ineffective hematopoiesis. Recently, 2 classification systems (the 5th edition of the World Health Organization...
7.
Common Driver Mutations in AML: Biological Impact, Clinical Considerations, and Treatment Strategies
Nong T, Mehra S, Taylor J
Cells
. 2024 Aug;
13(16).
PMID: 39195279
Next-generation sequencing of samples from patients with acute myeloid leukemia (AML) has revealed several driver gene mutations in adult AML. However, unlike other cancers, AML is defined by relatively few...
8.
Mehra S, Nicholls M, Taylor J
Int J Mol Sci
. 2024 Jul;
25(14).
PMID: 39062757
Bruton's tyrosine kinase (BTK), a non-receptor tyrosine kinase crucial for B cell development and function, acts downstream of the B cell receptor (BCR) in the BCR pathway. Other kinases involved...
9.
Cool A, Nong T, Montoya S, Taylor J
Trends Pharmacol Sci
. 2024 Jul;
45(8):691-707.
PMID: 39025681
Bruton's tyrosine kinase (BTK) inhibitors have revolutionized the treatment landscape for B cell lymphomas such as chronic lymphocytic leukemia (CLL). The first-in-class BTK inhibitor ibrutinib has recently been succeeded by...
10.
Chaudhry S, Beckedorff F, Jasdanwala S, Totiger T, Affer M, Lawal A, et al.
Leukemia
. 2024 Jul;
38(9):1894-1905.
PMID: 38997434
SF3B1 mutations frequently occur in cancer yet lack targeted therapies. Clinical trials of XPO1 inhibitors, selinexor and eltanexor, in high-risk myelodysplastic neoplasms (MDS) revealed responders were enriched with SF3B1 mutations....